News | September 23, 2024
Ind Swift Laboratories opens marketing office in New Delhi
This office will be the central hub for all operations related to companies ethical pharmaceutical business
This office will be the central hub for all operations related to companies ethical pharmaceutical business
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Stable profits, low leverage to keep credit profiles comfortable
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
